You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The diagnostics are capable of detecting fewer than two parasites per microliter of blood and would cost an estimated $.61 per test.
FIND has convened the Access to COVID-19 Tools Accelerator Diagnostic Pillar to supply 500 million tests to countries in the next year.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.
Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.
The company said it will look to obtain regulatory approval in additional countries to accelerate the analyzer's market introduction in Asia and Africa.
Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.
The company will donate full laboratory set-ups to the effort and provide training and education to implement screening programs.
The point-of-care system is designed to measure glycated hemoglobin levels in whole blood for use in the monitoring and management of diabetes.
Validation for the BioSure COVID-19 Antibody Self-Test, which provides results in 10 minutes and requires no training, is currently underway, the firms said.